Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Prednisone 5Mg Clear all
Completed Phase 2 Interventional Results available

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

NCT01393730
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Dutasteride, Prednisone
Drug
Lead sponsor
Mary-Ellen Taplin, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01017939
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, Prednisone, Dextromethorphan hydrobromide, Theophylline
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Beverly Hills, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Sep 5, 2026, 2:12 AM EDT
Not yet recruiting Phase 4 Interventional

Infliximab for Immune Checkpoint Inhibitor Associated AKI

NCT07683975
View directory record Official record
Conditions
Acute Kidney Injury, Acute Interstitial Nephritis
Interventions
Infliximab, Prednisone, prednisone (oral)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 5, 2026, 2:12 AM EDT
Withdrawn Phase 3 Interventional

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

NCT03532022
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
Chronocort®, Standard Care
Drug
Lead sponsor
Neurocrine UK Limited
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Morehead City, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 1 Interventional

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

NCT01155791
View directory record Official record
Conditions
Urologic Neoplasms, Prostate Cancer, Prostate Cancer Metastatic Disease
Interventions
Docetaxel, Biosyn, Prednisone
Drug
Lead sponsor
Sandy Srinivas
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 1 Interventional

Pazopanib, Docetaxel, Prednisone Prostate

NCT01385228
View directory record Official record
Conditions
Prostate Cancer
Interventions
Pazopanib, Docetaxel, Prednisone, Pegfilgrastim
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Chicago, Illinois • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

NCT02496585
View directory record Official record
Conditions
Lung Cancer, Lung Metastases
Interventions
Nintedanib, Prednisone, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
12
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 3 Interventional

High-dose Prednisone in Duchenne Muscular Dystrophy

NCT00110669
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisone
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
4 Years to 10 Years · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2011 · Synced Sep 5, 2026, 2:12 AM EDT
Withdrawn Phase 1 Interventional

LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel

NCT02182622
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Prednisone, LDE225
Drug
Lead sponsor
Martin Gutierrez
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 5, 2026, 2:12 AM EDT
Recruiting Phase 2 Interventional

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

NCT04812366
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab, Docetaxel, Niraparib 100mg Oral Capsule, Atezolizumab, Tazemetostat Pill, Capivasertib
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
18 Years and older · Male only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Sacramento, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

NCT02462252
View directory record Official record
Conditions
Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome
Interventions
BL-8040, horse anti-thymocyte globulin (hATG), Methylprednisolone, Cyclosporine
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

NCT00452387
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Mitoxantrone, Prednisone, Sorafenib
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
La Verne, California • Atlanta, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 4 Interventional Results available

Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients

NCT02953873
View directory record Official record
Conditions
Immunosuppression
Interventions
Tacrolimus Extended Release Capsule, Mycophenolate mofetil, Prednisone, Mycophenolate Sodium
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 5, 2026, 2:12 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02159690
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
Drug
Lead sponsor
Kenneth Pienta, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 4 Interventional Results available

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

NCT00596947
View directory record Official record
Conditions
Transplants and Implants
Interventions
Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
19 Years to 74 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer

NCT00348816
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, prednisone, Radical prostatectomy, Radiation therapy
Drug · Procedure · Radiation
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 1 Interventional

PK and Dose Escalation and Expansion Study of DST-2970

NCT04291664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone 5Mg Tab, DST-2970 (Abiraterone)
Drug
Lead sponsor
DisperSol Technologies, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Miami, Florida • New Orleans, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 5, 2026, 2:12 AM EDT
Recruiting Phase 3 Interventional

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 1 Interventional

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

NCT05276492
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic
Interventions
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log, Low-fat meal
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 5, 2026, 2:12 AM EDT
Terminated Phase 4 Interventional

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

NCT04773392
View directory record Official record
Conditions
Kidney Transplantation, Kidney Transplant Rejection
Interventions
Twice-daily Tacrolimus, Once-daily envarsus XR, Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG), Methylprednisolone, prednisone, Mycophenolate mofetil (MMF) or Mycophenolic acid (MPA), Azathioprine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 5, 2026, 2:12 AM EDT
Recruiting Phase 4 Interventional

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

NCT07258771
View directory record Official record
Conditions
Ulcerative Colitis Acute
Interventions
Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01468532
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
docetaxel, pasireotide, prednisone
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 5, 2026, 2:12 AM EDT
Completed Phase 2 Interventional

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

NCT03860987
View directory record Official record
Conditions
Castrate Sensitive Prostate Cancer
Interventions
goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 5, 2026, 2:12 AM EDT